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1. Introduction     
The multiple sclerosis (ME) is an illness degenerative chronicle of the central nervous 
system. At the moment is considered that it doesn't have cure although exists effective 
medication and the investigation on their causes is an active field of investigation.   
The objective of this article is to develop a model more precise, based on the use of the 
Artificial Neural netwrok (ANN), to study the evolution of the illness in the patients with 
EM. 
2. Important 
This article presents a model to study the evolution of the illness ME using ANN. The 
implementation and validation of the pattern was carried out in the programs of Biomedical 
Engineering and of Systems of the ITM.    
The article is organized in the following way: the first chapter presents an introduction to 
the ME, studying the possible forms of the evolution of the illness. In second chapter 
exposes the model of the evolution of the illness using ANN and the validation tests. The 
article concludes showing the main conclusions of this investigation. 
3. Information 
3.1 The multiple sclerosis 
A special study on the ME is beyond the environment of this unit.  In ((NATIONAL 
INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEN, 2010) offers an excellent 
treatment with specific references. In this section a brief revision is presented with the 
purpose of providing a basic knowledge on the matter. 
The ME is an illness degenerative and chronicle of the central nervous system. At the 
moment is considered that it doesn't have cure although exists effective medication and the 
search on their exact causes are ignored and is a field of active investigation.  
The ME can present a series of symptoms that appear in buds or that they progress slowly 
along the time. They are distinguished several subtypes of multiple sclerosis and many 
affected present forms different from the illness with the step of the time... 
Because of their effects on the central nervous system, it can have as consequence a reduced 
mobility and disability in the most severe cases. Fifteen years after the appearance of the 
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first symptoms, if it is not treated, at least the patients' 50% conserves a high degree of 
mobility. Less than 10% of the sick persons they die because of the consequences of the 
multiple sclerosis or of their complications. 
It is, after the epilepsy, the most frequent neurological illness among the young adults and 
the most frequent cause in paralysis in the western countries. It affects approximately at 1 of 
each 1000 people, in particular to the women. It is presented when the patients have 
between 20 and 40 years. (Noseworthy et to the., 2000; Rivera 2000). 
Description. The ME is characterized by two phenomena: 
Appearance of focuses spread in the brain and partially also in the spinal marrow caused by 
the attack of the system immune against the sheath of myelin of the nerves, like is illustrated 
in the figure 1.    
The neurons, and especially their axons is damaged by diverse mechanisms.  
 
 
Fig. 1. Myelin 
As a result, the neurons of the brain lose partial or totally their transmission capacity, 
causing the typical symptoms of drowsiness, tickling, spasms, paralysis, tires and alterations 
in the view. 
In the variant Remittent-Recurrent has also been detected in the nervous tissue, or cut of the 
axons of the neurons, that makes permanent sequels. 
Treatment. Cure doesn't exist for the ME. However we have been several medications that 
are effective in their treatment (Gutiérrez-Alvares et to the., 2001), braking the development 
of the illness and combatting the symptoms.    
The remittent-recurrent variant only has treatments approved by the FDA (Administration 
of Foods, for its initials in English - Food and Drug Administration) and the EMEA 
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(European Agency of medications - European Medicines Agency). At the moment, they are 
three interferons (Blackish et to the., 2003) (Avonex, -well-known Betaseron in Europe like 
Betaferon (The IFNB, 1993; Paty et. to the., 1993, Jacobs et at the 1996, (Yong et to the, 1998) 
and Rebif (PRISMS, 1998; PRISMS, 2001), a group of called polipéptidos Copaxone, a called 
immunosuppressive Mitoxantrone and finally an antibody called monoclonal Natalizumab 
and marketed as Tysabri. The clinical rehearsals (Freedman, 1998; Durelli et. to the., 2002; 
Panitch et to the, 2002; Clanet et to the, 2002) on the different medications they demonstrate 
that they are not comparable because they correspond to different study designs. 
The primary progressive ME is very difficult of trying. The corticosteroids to high dose 
every three months can have some effect. In principle a treatment preventive cash doesn't 
exist for the primary progressive ME. The treatment of the symptoms, and the rehabilitation 
by means of physiotherapy, occupational therapy, have an important paper. It is very 
important, equally, the evaluation on the part of a neuropsychologist to be able to approach 
any deficit cognitive that could be established. 
Epidemiology. It is believed that MS occurs when a combination of environmental factors in 
genetically predisposed to buy it. 
Environmental factors. In northern Europe, North America and Australasia continental one 
in 1,000 people suffers from MS. In Central Europe is the inflammatory disease most 
common central nervous system. In contrast, in the Arabian Peninsula, Asia, Central and 
South America continental frequency is much lower. Sub-Saharan Africa is extremely rare. 
With notable exceptions, there is a north-south gradient in the northern hemisphere and 
south-north in the southern hemisphere, with lower frequencies in the equatorial areas. The 
climate, diet, geomagnetism, toxins, sunlight, genetic factors and infectious diseases have 
been proposed as possible causes of these regional differences. It has been postulated that 
some environmental factor in childhood may play an important role in the development of 
MS in adult life. 
Genetic factors. MS occurs mainly in Caucasians. It is 20 times less common among 
Canadian Inuit than among other Canadians living in the same region. It is also rare among 
American Indian tribes of North America, Australian Aborigines and the Maori of New 
Zealand. These examples indicate that genetics plays an important role in the development 
of the disease. (Noseworthy et al, 2000) MS is not hereditary. However, the disease is 
influenced by the genetic constitution of the individual and has been shown that there are 
genes that are associated with an increased risk of contracting the disease. These genes, 
which are being studied, are not sufficient to diagnose the disease. 
Diagnosis. The diagnosis of MS is complex (Thompson et al.. 2000; Poser et al, 1983, Fazekas 
et al, 1988; Offenbacher et al, 1993; Paty et al., 1988). It requires evidence of a dissemination 
of lesions over time and space in the CNS. That means that not only must have at least two 
separate injuries verifiable by clinical symptoms or MRI, in addition there must be evidence 
of new symptoms or injuries in a range of 30 days. (McDonald et al, 2001) 
The conductivity studies of the optic nerve, sensory and motor also provide evidence of the 
existence of the disease, since the process of demyelination involves a reduction of 
conduction velocity of nerve signals. The study was done by comparing the reaction times 
with preset measurements. 
Symptoms. The central nervous system lesions that cause MS does not always manifest as 
clinical symptoms directly detectable and clearly attributable to the disease, which 
sometimes tends to minimize the first signs. However, the origin of MS is present and 
begins to progress. 
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Although in some instances at the beginning of MS accumulates little disability and quality 
of life is not too concerned, the reality is that the substrate of the disease is developing. 
There is abundant clinical and scientific evidence indicate that what happens in the early 
stages of MS, largely depends on its further development. In other words, injuries today in 
the central nervous system are the cause of disability in the morning, so that if not 
prevented now, tomorrow will be too late for recovery. MS detection is key as soon as 
possible to act in time. 
It has been shown that early treatment significantly reduced the number of shoots and their 
intensity. Affected individuals may exhibit a wide range of symptoms, but differ widely 
from each other, both in the type of symptoms and in their degree. In principle, can be 
classified according to the area affected the nervous system: derived from optic nerve 
damage, resulting from damage to the spinal cord (in particular those related to mobility are 
of this type) and derived from brain damage. 
The following are the most common: asthenia (fatigue), muscle loss, muscle weakness, 
uncoordinated movements, dysphagia (trouble swallowing), dysarthria (speech problems), 
respiratory failure, dyspnea (breathing problems) spasticity (muscle stiffness), muscle 
spasms, cramps, muscle twitching (small but widespread muscle vibration), sexual 
dysfunction, vision problems (loss, double vision, nystagmus), cognitive problems 
(difficulty performing simultaneous tasks, to follow instructions, loss of short-term memory, 
depression), emotional lability (inappropriate laughing and crying without psychological 
effects), constipation secondary to immobility. 
Types of MS: In most cases sclerosis begins with acute onset of symptoms in a space that 
varies from hours to days, usually called a flare, attack or episode. Later speaking of relapse. 
The first symptom is often the optic neuritis, an inflammation of the optic nerve that causes 
impaired vision and pain when moving the eye. However, not all patients with optic 
neuritis develop MS. Sensory disturbances such as numbness or tingling are also common 
early symptoms. In principle, MS can start with any of the symptoms associated with the 
disease. 
Benign MS. In benign MS cases after one or two attacks, the recovery is complete. The 
disease worsens over time and usually less severe symptoms. These cases are identified only 
when it is a small permanent disability after 10 or 15 years after the first attack, which was 
identified at the time as relapsing MS. In this case, loss of vision or sensory symptoms 
(numbness or tingling) as initial symptoms are signs of a benign prognosis. Disturbances in 
gait and fatigue are signs of a negative prognosis. 
Relapsing-remitting MS. Especially in the early stages of the disease, the symptoms diminish 
or disappear spontaneously over a period that can last from days to months. This type of 
course is called relapsing-remitting. New relapses may occur within weeks or several years 
and are unpredictable. These relapses may include the above symptoms and / or new ones. 
However, MRI studies show that nerve damage in these patients can continue even when 
symptoms have subsided. It has been known long ago that MS never sleeps, so the importance 
of preventive treatment is great. Many patients remain at this stage the rest of their life. 
Secondary progressive MS. In many cases, the disease changes after several years and 
symptoms begin to slowly progress with or without relapses tax. It is not known yet but its 
etiology. 
Primary progressive MS. 10% of all affected individuals have a chronic progress from the 
beginning without remission. It is called primary progressive and often appears with leg 
weakness and alterations in gait and urinary bladder. They appear to be degenerative and 
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inflammatory processes that play a dominant role in this type. In cases where the primary 
progressive form of relapse is usually imposed on talk of progressive relapsing. 
Other forms of multiple sclerosis, to be for many different diseases, which are grouped 
under the collective name of "border forms" of multiple sclerosis. (Noseworthy et al., 2000; 
Rivera, 2003) 
An overview of different types of MS, is shown in Figure 2. 
 
 
Fig. 2. Different types of evolution of MS 
Demyelination. In health, there is a barrier between the central nervous system and the 
blood called blood-brain barrier, which consists of endothelial cells lining the blood vessel 
walls. 
For unknown reasons, in patients with amyotrophic this barrier does not function well, and 
autoreactive T cells cross it. 
Since that time, an inflammatory process appears. The inflammation is provided by other 
immune cells and soluble factors, such as cytokine and antibody. Because of this abnormal 
behavior of the immune system, MS is considered an autoimmune disease. 
Widely accepted is that a particular subtype of lymphocytes, called CD4 cells, Th1-T, have a 
key role in the development of the disease. Under normal circumstances, these lymphocytes 
can distinguish between own and other cells. In a person with MS, however, the cells 
recognize healthy parts of the central system as foreign and attack them as they would a 
virus. In MS, the party attacked is myelin, a fatty substance that covers the axons of nerve 
cells and is important for proper nerve transmission. (Hafler et al, 1989) 
The inflammation eventually leads to the opening of the blood-brain barrier, which can lead 
to problems such as edema. It also causes the activation of macrophages, metalloproteinases 
and other proteases and cytokines. Eventually lead to the destruction of myelin, a process 
called demyelination. 
Remyelination. Original Oligodendrocytes form the myelin sheath are not able to recreate 
the cover once it is destroyed. However, the brain is able to recruit stem cells that migrate 
from other unknown regions of the brain, differentiate into mature oligodendrocytes and 
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recreate the myelin sheath. This new cover is often not as thick or effective as the original 
and repeated attacks remielinizaciones reaction will become less effective (Hauser et al., 
1986, Trapp et al, 1998), until a plaque around the axons damaged (Tintoré et al, 2001; 





Fig. 3. Plaques (a) by the degeneration of myelin (b). 
Remyelination is one of the reasons why, especially in the early stages of the disease, 
symptoms tend to diminish or disappear after days to months. 
3.2 Study case 
Respecting the confidentiality of a patient's medical information and confidentiality within 
ethical and legal framework in force, and himself as to the custody of the records of 
Magnetic Resonance, and not be subject to experimental research without their fully 
informed and free consent , is presented below for anonymous study of a patient diagnosed 
with MS since 2003, in control, receiving Betaferon Ampoules applied every 1.5 days. Her 
medical history (from the onset, January 2003 to March 2010), the number of relapses and 
MRI examinations performed, are illustrated in Figure 4. 
The results of the MRI examinations are as illustrated below. 
MR1 (June 2003). CERVICAL SPINE. 
Symptoms: Patient 28, female, with three-month history of pain in the cervical region 
radiating to the upper limbs, back and neck. 
Conclusion: One is transverse myelitis at the level of C2-C3 and C3-C4, involving mainly the 
left hemicord. Twelve months after the onset of the disease, the patient fully recovered with 
no sequelae. 
MR2 (January 2006). BRAIN AND CERVICAL SPINE. 
Symptoms: lower limb anesthesia. 
Conclusion: EM Process signed demyelinating type of activity. Probable secondary left 
hippocampal sclerosis. Twelve months after the start of the second relapse, the patient is left 
with permanent recovery (lower extremities are slightly grassy). 
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Fig. 4. Historical record of a patient with MS 
MR3 (September 2007). BRAIN AND CERVICAL SPINE. 
Symptoms: lower limb paresthesias. 
Conclusion: Board demyelinating left side up to C3. Described small central disc protrusion 
at C3-C4 and C5-C6. MS stable with respect to previous control in January 2006. 
MR4 (October 2008). CEREBRAL 
Symptoms: lower limb paresthesias, twitching. 
Conclusion: Injuries globular and plate engaging the white matter, periventricular, 
predominantly periatrial, there are also other injury involving the left cerebral pendulum. 
These alterations are stable with respect to the cranial MRI September 2007, without 
showing enhancement postcontraste no increase in their sizes. 
MR5 (March 2010). CEREBRAL 
Symptoms: lower limb paresthesias, twitching. 
Conclusion: Patients with MS DX unchanged compared to the 2008 study. There is emerging 
injury and alterations in the stable known time interval. Satisfactory. 
Below in Table 1 summarizes the patient's history with MS. 
 
Episode 
Extent of disease 
progression. 
Improvement 
achieved by the end 
of the episode. 
Time between 
episodes 
1 (Jun. 2003) 100% 100%  
2 (Ene. 2006) 100% 85% 30 meses 
3 (Sep. 2007) 50% 85% 20 meses 
4 (Oct. 2008) 50% 80% 13 meses 
5 (Mar. 2010) 50% 80% 12 meses 
Tabla 1. Registro histórico de recaídas. 
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3.3 Modeling the historical record of the disease ms with ANN. 
Theory and modeling of the ANN is inspired by the structure and functioning of nervous 
systems, where the neuron is the fundamental element. There are neurons of different 
shapes, sizes and lengths, and attributes that determine their function and utility. 
A detailed study of the ANN is beyond the scope of this unit. In [Row, 2000; Martin del Brio, 
2002] offers an excellent study with specific references. 
To solve the approximation problem posed in Figure 4, the use of a heuristic approach, 
based on intuition and experimentation to select the topology of the ANN. This will have an 
input neuron (time measured in months), one output neuron (Measurement of relapse) and 
two hidden layers, each with 15 neurons, as illustrated below. 
 
 
Fig. 5. Architecture of RNA used 
The model validation tests were performed using the Neural Network Toolbox for 
MATLAB ®. The weights of the network is randomly initialized once. We use the training 
algorithm for second order Trainlm be considered the fastest, with a maximum 3000 
iterations and a final error in the approximation of 0.01 
Figure 6 shows the curve Approximation to the historical series of relapses That Had the 
patient with MS in the Period from January 2003 to March 2010. As Shown, the ANN 
Properly mapping the time series. Note That the final error in the Approximation Was 0.01, 
Which Is Considered a good measure. 
4. Conclusions 
MS is a chronic inflammatory demyelinating disease of the central nervous system that 
causes progressive disability of the individual. After an initial clinical syndrome develops 
the form of the disease relapsing-remitting (RRMS) that leads to a secondary phase of 
progressive disability. The goal of treatment is to reduce the frequency and severity of 
relapse and delay the onset of the secondary phase. 
There are currently no established clinical evidence to allow a prognosis or to decide a 
therapeutic response to MS, although there is promising research that need to be confirmed, 
as the detection of anti-MOG antibodies (serum antibody against myelin glycoprotein of 
oligodendrocytes, Myelin oligodendrocyte glycoprotein) and anti-MBP (antibody against 
myelin basic protein, Myelin basic protein) as predictors of progression to disease 
introduced (Tintoré et al 2003). The uncertainty is one of the psychological aspects are more 
difficult to carry in MS. 
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TRAINLM, Epoch 115/3000, MSE 0.00096863/0.001, Gradient 0.143639/1e-009 
TRAINLM, Performance goal met. 
Fig. 6. Diagnosis of MS disease progression by using RNA. 
The aim of this paper is to develop a more accurate model based on the use of Artificial 
Neural Networks, to study the evolution of the disease in patients with MS. The final error 
obtained in approximating the time series of relapses was 0.01, which is considered a good 
measure. 
The method proposed to date to predict the efficiency of the treatment of relapsing-
remitting MS is by clinical criteria and monitoring of active lesions by MRI examinations. As 
a way of contributing to the reliability of diagnosis and treatment efficiency is proposed in 
this paper to map the time series records of relapse using a ANN. Its use helps the doctor 
evaluate, more agile, the variation of the disease and its impact in the medium and long 
term. 
Furthermore, long known that MS never sleeps, so the importance of preventive treatment is 
great. Many patients remain at this stage the rest of their life. In this case, using the model 
proposed in this paper helps the physician to improve their diagnoses in terms of disease 
trends. Likewise, the ANN used to evaluate the response has been the patient to the 
treatment of this disease, coupled with the clinical and MRI outcomes. With the ANN could 
be predicted more accurately in the first months of therapy if the patient responds or not to 
therapy. 
Moreover, the drugs used in the treatment of MS are only "partially effective" (Anderson, 
1997). Therefore, physicians need to evaluate their response by MRI, and clinical criteria that 
include measuring the frequency of relapses and measuring the degree of disability 
progression. In this case, the use of an ANN, helps the doctor to study the variation of the 
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disease and raise more swiftly changes when treatment is not effective before they produce 
a greater neurological damage. 
The diagnosis of MS using ANN during treatment to detect changes in the state of 
neurological inflammation of the sick and to assess the effect of different drugs on injuries. 
The effectiveness of the diagnosis in ANN depend on the correct measurement of the 
frequency of relapses and the degree of progression of the disease. 
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